Apellis Pharmaceuticals (APLS) Stock Statistics & Valuation Metrics

Apellis Pharmaceuticals has a market cap or net worth of $2.17B. The enterprise value is $2.23B.

Apellis Pharmaceuticals has 125,682,260 shares outstanding. The number of shares has decreased by -2.65% in one year.

Apellis Pharmaceuticals’s return on equity (ROE) is -0.87 and return on invested capital (ROIC) is -23.50%.

The current PE Ratio of Apellis Pharmaceuticals is -19.98. Apellis Pharmaceuticals’s PEG ratio is -0.50.

In the last 12 months, Apellis Pharmaceuticals had revenue of 781.37M and earned -197.88M in profits. Earnings per share was -1.60.

In the last 12 months, operating cash flow was -87.87M and capital expenditures -403.00K, giving a free cash flow of -88.27M billion.

Apellis Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Apellis Pharmaceuticals upcoming earnings date is Aug 11, 2025, TBA Not Confirmed.

Apellis Pharmaceuticals as a current ratio of 4.25, with Debt / Equity ratio of 205.56%

In the past 12 months, Apellis Pharmaceuticals has paid 1.16M in taxes.

Apellis Pharmaceuticals EV to EBITDA ratio is -25.96, with an EV/FCF ratio of -45.46.

Apellis Pharmaceuticals has $411.29M in cash and marketable securities with $469.78M in debt, giving a net cash position of $58.49M billion.

Gross margin is 84.82%, with operating margin of -21.11%, and net profit margin of -25.32%.

The average price target for Apellis Pharmaceuticals is $38.06, which is 11.43% higher than the current price. The consensus rating is Moderate Buy